Molecular Diagnostics and Therapeutics Group
Susan Heavey is a cancer research fellow interested in use of ex vivo models to predict treatment response in cancer.
She undertook her Bachelor's degree, post-graduate diploma, PhD and first postdoctoral research projects in Dublin Ireland, before joining UCL in 2016. Here she spent two years initiating and developing the PEOPLE pathway, which enables a number of downstream research projects to benefit from access to high quality human prostate cancer specimens sampled using a new MRI targeting technique. This multidisciplinary undertaking connects researchers across wide ranging disciplines with clinical, pathological and surgical teams to deliver meaningful research geared towards patient benefit. During this two year postdoc position she also worked on the 100,000 Genomes Project with Genomics England, and a number of clinical trials, most notably INNOVATE and FORECAST.
In 2018 Susan began a Travelling Prize Fellowship funded by Prostate Cancer UK, based between UCL and Cold Spring Harbour Laboratory in America. Her fellowship focuses on spatial transcriptomic approaches to assess pre-clinical drug combinations in an ex vivo human prostate cancer model, downstream of the PEOPLE pathway.
Apparatus for Histological Validation of and Magnetic Resonance Imaging of the Human Prostate.
Frontiers in oncology , 2017 | Pubmed ID: 28393049
Immunohistochemical biomarker validation in highly selective needle biopsy microarrays derived from mpMRI-characterized prostates.
The Prostate 12, 2018 | Pubmed ID: 30073682
VERDICT MRI validation in fresh and fixed prostate specimens using patient-specific moulds for histological and MR alignment.
NMR in biomedicine 05, 2019 | Pubmed ID: 30779863
PEOPLE: PatiEnt prOstate samPLes for rEsearch, a tissue collection pathway utilizing magnetic resonance imaging data to target tumor and benign tissue in fresh radical prostatectomy specimens.
The Prostate May, 2019 | Pubmed ID: 30807665
VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient.
Radiology May, 2019 | Pubmed ID: 30938627
Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC.
Lung cancer (Amsterdam, Netherlands) Sep, 2019 | Pubmed ID: 31446998
The Oncogene Metadherin Interacts with the Known Splicing Proteins YTHDC1, Sam68 and T-STAR and Plays a Novel Role in Alternative mRNA Splicing.
Cancers Aug, 2019 | Pubmed ID: 31450747
关于 JoVE
版权所属 © 2024 MyJoVE 公司版权所有,本公司不涉及任何医疗业务和医疗服务。